On February 21, 2025, FDA declared the national shortage of semaglutide injections resolved and signaled tighter enforcementwhile allowing limited discretion to avoid disrupting active treatment
First therapeutic testing of GLP-1 in humans By the late 1980s two versions of GLP-1 were separately beginning to be tested for their therapeutic potential
In a complementary approach, exenatide-functionalized DFO NPs effectively chelated excess iron and preserved dopaminergic neurons in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model [207]
Patients with histories of depression, anxiety, or other psychiatric conditions should discuss these thoroughly with prescribers
Insurance Coverage and Prior Authorization Support Navigating insurance for GLP-1 weight loss medications is often challenging, but Klinic makes it straightforward
One mouse and one datapoint in vehicle group was omitted from analysis as they had insulin levels outside the assay range